A Word of Caution on New and Revolutionary Diagnostic Tests

Cancer Cell

Volumn 29, Issue 2, 2016, Pages 141-142

  Diamandis, Eleftherios P ^a,b,c  

^a MOUNT SINAI HOSPITAL   (Canada)

^b UNIVERSITY HEALTH NETWORK   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; PROSTATE SPECIFIC ANTIGEN; TUMOR MARKER;

CANCER DIAGNOSIS; DIAGNOSTIC TEST; HUMAN; LETTER; PREDICTIVE VALUE; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; FEMALE; GENETICS; MALE; METABOLISM; NEOPLASM; SIGNAL TRANSDUCTION; THROMBOCYTE;

BIOMARKERS, TUMOR; BLOOD PLATELETS; FEMALE; HUMANS; MALE; NEOPLASMS; SIGNAL TRANSDUCTION;

EID: 84958595448     PISSN: 15356108     EISSN: 18783686     Source Type: Journal    
DOI: 10.1016/j.ccell.2016.01.003     Document Type: Letter

References (5)

1. Best M.G., Sol N., Kooi I., Tannous J., Westerman B.A., Rustenburg F., Schellen P., Verschueren H., Post E., Koster J., et al. RNA-Seq of tumor-educated platelets enables blood-based pan-cancer, multiclass, and molecular pathway cancer diagnostics. Cancer Cell 2015, 28:666-676.
2. Diamandis E.P. Analysis of serum proteomic patterns for early cancer diagnosis: drawing attention to potential problems. J. Natl. Cancer Inst. 2004, 96:353-356.
3. Diamandis E.P. Cancer biomarkers: can we turn recent failures into success?. J. Natl. Cancer Inst. 2010, 102:1462-1467.
4. Diamandis E.P. The failure of protein cancer biomarkers to reach the clinic: why, and what can be done to address the problem?. BMC Med. 2012, 10:87.
5. Diamandis E.P., Li M. The side effects of translational omics: overtesting, overdiagnosis, overtreatment. Clin. Chem. Lab. Med. 2015, 10.1515/cclm-2015-0762.